Accurate Measurement of Viral Clearance in Early-Phase Antiviral Studies in Coronavirus Disease 2019
- 21 August 2025
- journal article
- Published by Oxford University Press (OUP) in The Journal of Infectious Diseases
- Vol. 233 (2) , e582-e584
Abstract
No abstract availableFunding Information
- Wellcome Trust (223195/Z/21/Z)
- Wellcome Trust (093956/Z/10/C)
- Wellcome Trust (223253/Z/21/Z)
- National Institute for Health and Care Research (ACF-2023-323 13-012)
This publication has 6 references indexed in Scilit:
- The Choice of Viral Load End Point in Early Phase Trials of COVID-19 Treatments Aiming to Reduce 28-Day Hospitalization and/or DeathThe Journal of Infectious Diseases, 2025
- Temporal changes in SARS-CoV-2 clearance kinetics and the optimal design of antiviral pharmacodynamic studies: an individual patient data meta-analysis of a randomised, controlled, adaptive platform study (PLATCOV)The Lancet Infectious Diseases, 2024
- Viral clearance as a surrogate of clinical efficacy for COVID-19 therapies in outpatients: a systematic review and meta-analysisThe Lancet Microbe, 2024
- The relationship between viral clearance rates and disease progression in early symptomatic COVID-19: a systematic review and meta-regression analysisJournal of Antimicrobial Chemotherapy, 2024
- Characterizing SARS-CoV-2 Viral Clearance Kinetics to Improve the Design of Antiviral Pharmacometric StudiesAntimicrobial Agents and Chemotherapy, 2022
- Clinical relevance of nasopharyngeal SARS-CoV-2 viral load reduction in outpatients with COVID-19Journal of Antimicrobial Chemotherapy, 2022